Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D

Merck KGaA has rejigged a 2015 drug development deal with NASDAQ-listed Intrexon, swapping rights to potential CAR-T therapies for stock in the biology specialist.

T-cells
Merck KGaA says deal lets it stay invested in CAR-T field while focusing its R&D efforts • Source: Shutterstock

Germany's Merck KGAA has opted not to take a hands-on approach in developing Chimeric Antigen Receptor T-cell therapies and has instead changed its previous drug development deal with US-based Intrexon Corp., trading rights to potential CAR-T therapies for stock in the biotech.

Under the new arrangement, announced Dec. 20, Intrexon will issue the family-controlled German pharma $150m in shares and a $25m...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.